Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Condylomata Acuminata 4Papillomavirus Infections 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Cancer Survivor 1

Interventions

Cisplatin 3fludarabine phosphate 2fludarabine 2aldesleukin 2Radiation 2Platinum 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Cyclophosphamide 2Congresses as Topic 2Brachytherapy 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 21,2-diaminocyclohexaneplatinum II citrate 2rocakinogene sifuplasmid 1durvalumab 1alovudine 1adavosertib 1Vaccines, Synthetic 1VGX-3100 1Sonazoid 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Magnetic Resonance Spectroscopy 1MEDI0457 1Interleukin-2 1Immunoglobulin G 1Fondaparinux 1Fluorodeoxyglucose F18 1Fentanyl 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vaginal Neoplasms × Vaccines, Synthetic × Clear all
NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡